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The major cellular event in the development and progression of liver ﬁbrosis is the activation of hepatic stellate cells (HSCs).
Activated HSCs proliferate and produce excess collagen, leading to accumulation of scar matrix and ﬁbrotic liver. As such, the
induction of activated HSC deathhas been proposedasameans toachieve resolution ofliver ﬁbrosis. Herewedemonstrate that
cannabidiol (CBD), a major non-psychoactive component of the plant Cannabis sativa, induces apoptosis in activated HSCs
through a cannabinoid receptor-independent mechanism. CBD elicits an endoplasmic reticulum (ER) stress response,
characterized by changes in ER morphology and the initiation of RNA-dependent protein kinase-like ER kinase-, activating
transcription factor-6-, and inositol-requiring ER-to-nucleus signal kinase-1 (IRE1)-mediated signaling cascades. Furthermore,
CBD induces downstream activation of the pro-apoptotic IRE1/ASK1/c-Jun N-terminal kinase pathway, leading to HSC death.
Importantly, we show that this mechanism of CBD-induced ER stress-mediated apoptosis is speciﬁc to activated HSCs, as it
occursinactivated humanandratHSC lines,andinprimary invivo-activatedmouseHSCs,butnotinquiescentHSCsorprimary
hepatocytes from rat. Finally, we provide evidence that the elevated basal level of ER stress in activated HSCs has a role in their
susceptibility to the pro-apoptotic effect of CBD. We propose that CBD, by selectively inducing death of activated HSCs,
represents a potential therapeutic agent for the treatment of liver ﬁbrosis.
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Liver ﬁbrosis is the tenth leading cause of death in the US,
affecting over 400000 patients.
1 As the common wound-
healing response to liver injury, it is the outcome of many
chronic liver diseases, including viral and autoimmune
hepatitis, alcoholic liver disease, and obesity-related liver
disease.
2 Because of the high incidence of cirrhosis and liver
failure that results from ﬁbrosis, identifying pharmacological
treatments that can halt the progression of, or even reverse,
ﬁbrosis is of utmost clinical importance. The activation of
hepatic stellate cells (HSCs) in response to liver injury is
considered a key cellular event underlying hepatic ﬁbrogen-
esis. HSC activation refers to the transdifferentiation of
quiescent HSCs into proliferative and contractile myoﬁbro-
blast-like cells. These activated HSCs secrete excess
extracellular matrix (ECM) proteins, predominantly collagen
type I, leading to the accumulation of scar matrix, and
ultimately hepatic ﬁbrosis.
3 As HSCs have a critical role in
ﬁbrogenesis, the elimination of activated HSCs through cell
death has been proposed as a mechanism to attenuate or
reverse liver ﬁbrosis.
4 Therefore, much research has been
aimed at identifying compounds that target activated HSCs
and lead to HSC death.
Recent studies have investigated the effects of cannabi-
noids in liver disease, highlighting a role for the endocanna-
binoid system (reviewed in Tam et al.
5) The endogenous
cannabinoid ligand anandamide (AEA), a type I/type II
cannabinoid receptor (CB1R/CB2R) agonist, has been shown
to induce necrosis in activated HSCs, albeit at high
concentrations ranging from 25mM to 100mM.
6 However,
because CB1R is highly expressed in the central nervous
system, the prospective use of AEA as an effective
therapeutic agent is diminished by its potential to cause
adverse effects at such high concentrations. Thus, the
identiﬁcation of alternative cannabinoids that effectively
induce HSC death at lower concentrations, while exhibiting
little or no receptor activity, may offer more appealing drug
candidates.
Cannabidiol (CBD) is the major non-psychoactive plant-
derived cannabinoid. In recent years, CBD has been shown to
act in vivo as an anti-inﬂammatory molecule
7,8 as an
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9 and importantly, as an anti-proliferative compound
inducing a loss in viability in a number of tumor cell lines.
10–12
Given the anti-proliferative properties of CBD, we hypothesized
that this compound could exhibit therapeutic potential in the
context of liver ﬁbrosis by preventing proliferation of activated
HSCs. Here, we ﬁnd that CBD induces apoptosis in activated
HSCs,andweidentifyendoplasmicreticulum(ER)stressasthe
molecular mechanism underlying this process.
Results
CBD induces activated HSC apoptosis in a cannabinoid
receptor-independent manner. To investigate the potential
of CBD and other cannabinoid ligands to induce activated
HSC death, we treated cultured activated HSCs, isolated
from livers of rats that were fed an 8-month ethanol diet
13
(see details in Materials and Methods), with increasing
concentrations of different cannabinoids for 8h, and
measured cell viability using an acid phosphatase assay.
Incubation of cells with up to 10mM of either AM630 (CB2R
antagonist), JWH133 (CB2R agonist), PF514273 (CB1R
antagonist), AM251 (CB1R antagonist), or ACEA (CB1R
agonist) had little or no effect, whereas 5mM of either CBD or
CP55940 (CB1R/CB2R agonist) was sufﬁcient to cause
B60% and 90% loss of viability, respectively. In contrast to
exogenous ligands, 20mM AEA (endogenous CB1R/CB2R
agonist) was required to achieve a similar effect, whereas
2-arachydonoyl glycerol (2-AG, endogenous CB1R/CB2R
agonist) treatment resulted in no signiﬁcant change in the
survival of these cells (Figure 1a).
In parallel, we investigated the ability of these cannabinoids
to kill activated HSCs by examining the presence of cleaved
poly-(ADP ribose)-polymerase (PARP), a marker for cell
death, following 5mM treatment of cells. Among these
compounds, only AEA and CBD were able to promote
activated HSC death, as indicated by western blot analysis
of PARP cleavage (Figure 1b), in agreement with the results
obtained with the cell viability assay. Upon further examina-
tion, we found that CBD induced activated HSC death in a
dose- and time-dependent manner, detectable after 6h with
5mM treatment (Figure 1c). We then conﬁrmed the induction
of apoptosis by CBD using ﬂow cytometric analysis of FITC-
Annexin V staining (Figure 1d).
In order to characterize the mechanism through which CBD
causes apoptosis, we ﬁrst investigated whether CBD was
acting through cannabinoid receptors CB1Ro rC B 2R. We
found that blocking CB1Ro rC B 2R had no effect on CBD-
induced PARP cleavage (Figure 2a) and activated HSC
viability (Figure 2b), in contrast to the death induced by
CP55940, which appears to be mediated at least, in part, by
CB2R. Co-treatment with the CB2R antagonist AM630
decreased CP55940-induced cell death by over 50% (data
not shown). These results support a cannabinoid receptor-
independent mechanism for CBD-induced apoptosis.
CBD causes a change in morphology of the ER in
activated HSCs through induction of ER stress. During
the course of our experiments, we noticed marked changes
in the morphology of CBD-treated activated HSCs. The
presence of distinct structures surrounding the nucleus
suggested an effect of CBD on the ER (Figure 2c). This
was supported by an alteration in the distribution and
localization of the ER chaperone calnexin, with the
disappearance of uniform network-like ER structure and the
formation of perinuclear vacuole-like structures (Figure 2d).
This was further conﬁrmed by electron microscopy showing
that CBD treatment caused ER dilation (Figure 2e). These
changes in ER morphology suggested that CBD induces ER
stress.
We further investigated the effect of CBD on the ER in the
activated HSCs by examining changes in the expression of
calnexin, as well as the transcription factor C/EBP (CCAAT/
enhancer-binding protein) homologous protein (CHOP), a
major marker of prolonged ER stress. Western blot analysis
showed that CBD treatment led to increased expression of
bothcalnexinandCHOP(Figure2f).Furthermore,upregulation
of CHOP, an important potentiator of pro-apoptotic signaling
following ER stress, provided evidence that ER stress may
mediate CBD-induced apoptosis of activated HSCs.
CBD promotes apoptosis and ER stress in activated
HSCs, but not in control HSCs or primary
hepatocytes. In order to assess the speciﬁcity of CBD-
induced apoptosis and ER stress, we examined the effect of
CBD on the expression of PARP, calnexin, and CHOP in
different cell lines, as well as in primary cells. We ﬁrst
compared HSCs from ethanol-treated rats with HSCs from
control rats.
13 HSCs from control rats exhibit a markedly
lower activation state as compared with HSCs from ethanol-
treated rats, indicated by 20-fold lower expression of alpha
smooth muscle actin (aSMA; see Figure 3a, inset). Upon
comparing the effect of treatment with 5mM CBD in these
cells, we found that CBD did not alter PARP, calnexin, and
CHOP expression in control HSCs, suggesting that the pro-
apoptotic and ER stress effects of CBD were speciﬁc to the
activated HSC phenotype (Figure 3a).
In primary in vivo-activated mouse HSCs and in LX-2 cells
(immortalized human HSC line derived from cirrhotic pa-
tient
14), CBD led to PARP cleavage, upregulation of calnexin,
and induction of CHOP expression, consistent with what we
observed in activated HSCs from rats (Figures 3b and c). In
contrast, CBD treatment did not induce PARP cleavage or
upregulationofcalnexinandCHOPinprimaryrathepatocytes
(Figure 3d), conﬁrming the speciﬁcity of the pro-apoptotic
effect of CBD to activated HSCs.
To further examine the effect of CBD across different cell
types, we compared the viability of HSCs from control rats,
HSCs from ethanol-treated rats, and primary rat hepatocytes
under 0–20mM range of CBD treatment. As shown before,
5mM CBD was sufﬁcient to cause B60% decrease in viability
of HSCs from ethanol-treated rats, but not in HSCs from
control rats, for which 10mM CBD was required to induce a
signiﬁcant loss that occurs to an even lesser extent (B40%
reduction). In contrast to HSCs, primary rat hepatocytes
maintained maximal viability under treatment with up to 20mM
CBD(Figure3e).Altogether,theseﬁndingssuggestthatCBD,
in a dose-dependent manner, speciﬁcally targets activated
HSCs to cause death.
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Cell Death and DiseaseCBD induces PERK-, ATF6-, and IRE1-mediated ER
stress response in activated HSCs. We further
investigated the mechanism for CBD-induced ER stress
and apoptosis by characterizing the CBD-induced changes in
the major mediators of ER stress signaling as described
below. Cells respond to ER stress through a protective
mechanism termed the unfolded protein response (UPR) in
order to restore normal ER function. Upon stressful stimulus,
this adaptive response is initiated by the repression release
of three ER transmembrane proteins – PRKR (RNA-
dependent protein kinase)-like ER kinase (PERK), ATF6,
and inositol-requiring ER-to-nucleus signal kinase-1 (IRE1) –
from the ER chaperone glucose-regulated protein 78kDa
(GRP78). The subsequent activation of these ER stress
sensors initiates a cascade of signaling events that result in
the expression of genes that are critical for overcoming ER
stress, including transcription factors and molecular
chaperones
15,16 (Figure 4a).
Release of PERK from GRP78 allows PERK activation
through receptor autophosphorylation. Activated PERK can
phosphorylate and inhibit eukaryotic translation initiation
factor 2a (eIF2a), potentiating the eIF2a-independent transla-
tion and nuclear translocation of activating transcription factor
(ATF)-4 to induce gene expression of chaperones and
transcription factors such as CHOP. In activated HSCs, we
found that CBD induced phosphorylation of PERK at 2h,
PARP
β-Actin
1 0.4 0.4 0.9 0.8 2.5 0.7 2.1 0.4
DMSO
AM630
JWH
PF
AM251
CBD
ACEA
AEA
2-AG
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
JWH PF AM251
CBD
ACEA
AEA 2-AG
CP55940
PARP
β-Actin
116 kDa
89 kDa
42 kDa
Time
(hours)
CBD
12 6 02 4 1 2 6 02 4 1 2 6 02 4
1 μM2   μM5   μM
1 1.7 0.7 0.5 1 0.5 1.7 0.7 1 3.6 3.7 3.3
AM630
[Ligand] (μM)
[Ligand] (μM)
10 5 1 01 0 5 1 01 0 5 1 01 0 5 1 01 0 5 1 01 0 5 1 0
10 5 2 1 0 15 20 10 5 2 1 0 15 20 10 5 2 1 0 15 20
5.06 25.2
7.86 61.9
8.82 42.6
6.24 42.4
0.25 54.1
20.8 24.8
105
105
104
104
103
103
102
102
0
01 0 5 104 103 102 01 0 5 104 103 102 01 0 5 104 103 102 0
2.17
4.22 92.4
1.21
AnnexinV
PI
0
20
40
60
80
100
120
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
0
20
40
60
80
100
120
Figure 1 CBD induces apoptosis in activated HSCs. (a) Cell viability of activated rat HSCs was determined using an acid phosphatase assay following serum starvation
and8-htreatmentwithindicatedconcentrationsofcannabinoidligands.Cellsurvivalispresentedaspercentofacidphosphataseactivityinvehicle-treatedcells,expressedas
mean±S.E.M.oftriplicateexperiments.AM630,CB2Rantagonist;JWH(JWH133),CB2Ragonist;PF(PF514273),CB1Rantagonist;AM251,CB1Rantagonist;ACEA,CB1R
agonist; CP55940, CB1R/CB2R agonist; AEA, endogenous CB1R/CB2R agonist; 2-AG, endogenous CB1R/CB2R agonist. (b) Cell death was determined by western blot
analysis of cleaved PARP in activated-rat HSCs, following 12-h incubation in serum-free media in the presence of either vehicle (DMSO) or 5mM of indicated cannabinoid
ligands. PARP cleavageis expressed as cleaved PARP over total PARP. (c) PARP cleavagewas examined as in (b) in activatedrat HSCs treated with CBD for the indicated
concentrations and time periods. Western blots are representative of n¼three experiments. (d) Activated rat HSCs were incubated in serum-free media in the absence or
presenceof5mMCBDfor2,4,and8h,thenstainedforFITC-AnnexinVandpropidiumiodide(PI).Cellsweresortedandanalyzedbyﬂowcytometry.Thepercentageofcells
that are either negative or positive for Annexin V and/or PI is indicated in the appropriate quadrant of each panel
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Cell Death and Diseasefollowed by phosphorylation of eIF2a at 4h (Figure 4b). In line
with this, we also detected a time-dependent accumulation of
ATF4 in the nucleus (Figure 4c).
Upon release from GRP78, ATF6 is cleaved and translo-
cated to the nucleus to induce CHOP and X-box-binding
protein-1 (XBP1) expression. Western blot analysis showed
that CBD induced accumulation of cleaved ATF6a in the
nucleus (Figure 4c), indicating activation of the ATF6-
mediated ER stress response.
Release of IRE1 from GRP78 during the UPR is followed by
IRE1 autophosphorylation and phospho-IRE1-mediated
excision of a 26-nucleotide intron from XBP1 mRNA,
facilitating nuclear translocation of spliced XBP1 (XBP1s)
protein and induction of expression of genes such as
P58
IPK.
17 CBDtreatment ofactivated HSCs ledto anincrease
in phosphorylated IRE1, accompanied by slight induction of
P58
IPK expression (Figure 4b). We also found that CBD
induced splicing of XBP1 mRNA in a time- and dose-
dependent manner (Figure 4d). Moreover, a sharp increase
in nuclear XBP1s protein was detected from 2–8h of
treatment (Figure 4c), supporting CBD-induced activation of
the IRE1-mediated ER stress-signaling cascade.
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Figure 3 Pro-apoptotic effect of CBD is speciﬁc to activated HSCs. (a) HSCs from control or ethanol-fed rats, (b) primary mouse in vivo-activated HSCs, (c) LX-2 cells
(human HSC line derived from cirrhotic patient), and (d) primary rat hepatocytes were incubated in serum-free media with 5mM CBD for 0–8h. Cell lysates were subjected to
western blot analysis and probed for PARP, calnexin, and CHOP to detect cell death and ER stress. (e) Acid phosphatase activity was measured in order to determine cell
viabilityfollowingtreatmentwithindicatedconcentrationsofCBDfor8hinHSCsfromcontrolrats,HSCsfromethanol-fedrats,andprimaryrathepatocytes.Inset,westernblot
analysisof a-SMAexpressionin HSCsfrom eithercontrolor ethanol-fedrats. Westernblots andcell survivalassaysare representativeof n¼three independent experiments
Figure2 CBDinducesERdilationandexpressionofERstressmarkers.(a)ActivatedratHSCswereincubatedfor6hinserum-freemediawith5mMCBDinthepresence
or absence of either 1mM AM251 or 1mM AM630. Cell lysates were subjected to western blot analysis and probed for cleaved PARP to detect cell death. **Po0.01 versus
control (Student’s t-test). Representative of n¼three independent experiments. (b) Cell viability of activated rat HSCs treated with 5mM CBD in the presence or absence of
1mMAM251or 1mM AM630was determined usingtheacid phosphatase assayas describedin Materials andMethods.(c) Vehicle-or 5mMCBD-treatedactivatedrat HSCs
were visualized by light microscopy at 20 magniﬁcation after 4-h treatment. (d) Immunoﬂuorescent staining of calnexin (green) in activated rat HSCs. Activated HSCs were
incubatedinserum-freemediawitheithervehicleor5mMCBDfortheindicatedtimeperiods.ThecellswereﬁxedandprocessedforimmunostainingasdescribedinMaterials
and Methods. Nuclei were stained with DAPI (blue). Cells were visualized at 63 magniﬁcationby confocal microscopy. (e) Activated rat HSCs were incubated in serum-free
mediainthepresenceorabsenceof5mMCBDfor4h,thenﬁxedandprocessedforelectronmicroscopy.Cellswereimagedat12000 magniﬁcation.Whitearrowsindicate
the ER. (f) Activated rat HSCs were incubated in serum-free media for 0–24h with indicated concentrations of CBD. Cell lysates were subjected to western blot analysis and
probed for CHOP and calnexin. Representative of n¼three independent experiments
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Cell Death and DiseaseInduction of the ER stress response by CBD was further
conﬁrmed by an increase in expression of the UPR genes
ATF4, ATF6, CHOP, and XBP1. Although 2mM CBD
treatment for 6h induced signiﬁcant increase in transcript
levels of ATF4, ATF6, and CHOP, 5mM CBD led to even
greater upregulation of these genes at earlier time points
(Figure 4e).
Taken together, these results demonstrate that CBD
treatment leads to the induction of all three signaling arms of
the ER stress response in activated HSCs, resulting in
signiﬁcant upregulation of UPR genes and transcription
factors. Along with our observation that CBD leads to
apoptosis in activated HSCs, this provided strong evidence
for ER stress as the underlying mechanism mediating the
CBD-induced apoptotic response.
CBD promotes ER stress-induced apoptosis through
activation of the IRE1/ASK1/JNK pathway in activated
HSCs. In order to link the induction of ER stress to CBD-
mediated cell death, we examined signaling events
downstream of the UPR that trigger apoptosis. IRE1 has
been shown to be pro-apoptotic by activating apoptosis
signal-regulating kinase 1 (ASK1) through dephosphorylation
of its Ser967 residue. Activated ASK1 leads to
ER stress
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Figure4 CBDinducesERstressresponse.(a)SchematicrepresentationofthesignalingpathwayscharacterizingtheERstressresponse.In(b)through(e),activatedrat
HSCs were incubated in serum-free media with 5mM CBD, unless indicated otherwise, for the indicated time periods and processed for either (band c) western blot, (d)R T - P C R ,or
(e) qRT-PCR analysis of ER stress mediators. (b) Whole cell lysates were subjected to western blot analysis and probed for phospho-PERK, phospho-eIF2a, phospho-IRE1,
and P58
IPK to detect thePERK- and IRE1-mediated arms of the ER stress response.(c) Cell lysatesand nuclear extracts weresubjected to western blot analysisand probed
for ATF4, cleaved ATF6a, and XBP1s to detect the presence of ER stress transcription factors in the nucleus. (d) Total RNA was extracted from cells and reverse transcribed
to obtain cDNA used for PCR with primers speciﬁc for XBP1. Spliced XBP1 was detected by agarose gel electrophoresis. (e) Real-time RT-PCR was carried out with gene-
speciﬁc primers for ATF4, ATF6, CHOP, and XBP1 to detect relative mRNA levels at the indicated time points. Results are normalized to GAPDH, hypoxanthine-guanine
phosphoribosyltransferase, and RNA polymerase II, and expressed as fold change over control±S.E.M. (n¼three independent experiments in triplicate). *Po0.05;
**Po0.01; ***Po0.001 versus control (Student’s t-test)
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Cell Death and Diseasephosphorylation of c-Jun N-terminal kinase (JNK), which
then promotes a series of downstream pro-apoptotic
events.
18–20 As shown before (Figure 4b), we found that
CBD leads to IRE1 phosphorylation. In addition, CBD
induced dephosphorylation (activation) of ASK1, followed
by an increase in phosphorylation (activation) of JNK. This
cascade was activated in LX-2 cells, in cultured activated rat
HSCs, and in primary in vivo-activated mouse HSCs (Figures
5a–c). Furthermore, overexpression of dominant-negative
(DN) IRE1a in activated mouse HSCs (Figure 5d) prevented
JNK phosphorylation and protected cells from apoptosis
induced by CBD (Figure 5e). Expression of the DN IRE1a
also led to a marked decrease in XBP1s mRNA in DN IRE1a-
expressing activated HSCs after CBD treatment (Figure 5f),
conﬁrming the decreased activity of IRE1a. In addition, we
found that JNK inhibitor protected activated HSCs from the
apoptotic effect of CBD, decreasing PARP cleavage by over
50% (Figure 5g), and restoring cell viability to near maximal
(Figure 5h). These ﬁndings indicate that CBD triggers
apoptosis through ER stress-mediated activation of the
IRE1/ASK1/JNK pathway.
Blocking ER stress protects against CBD-induced
apoptosis in activated HSCs. In order to investigate
further the role of ER stress in CBD-induced apoptosis, we
downregulated ATF4, a transcription factor induced upon
activation of PERK in the UPR, in activated mouse HSCs.
This resulted in a signiﬁcant decrease in CHOP induction and
cell death caused by CBD (Figure 6a), suggesting the
importance of the PERK-mediated arm of the ER stress
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blot analysis in (a) LX-2 cells, (b) HSCs from ethanol-fed rats, and (c) primary mouse in vivo-activated HSCs, following incubation in serum-free media with 5mM CBD for
0–8h.(d)ExpressionofDNIRE1ainJS1cells(mouseactivatedHSCs)wasassessedbyRT-PCRusingprimersspeciﬁcforthemouseandhumanIRE1a.Wild-typeJS1and
LX-2 cells were used as controls. Gel-puriﬁed PCR products were sequenced to conﬁrm presence of the mutated IRE1a (K599A DN IRE1a). (e) JS1 cells expressing DN
IRE1a were treated with 5mM CBD in serum-free media for 0–4h. Expression of PARP and phospho-JNK was determined by western blot analysis and is presented as fold
over vehicle±S.E.M. for either control or DN IRE1a-expressing JS-1 cells, n¼three independent experiments. (f) JS1 cells expressing DN IRE1a were treated with CBD as
in (e), and then harvested for total RNA isolation and RT-PCR with XBP1-speciﬁc primers. Spliced XBP1 was detected by agarose gel electrophoresis. (g) LX-2 cells were
treated with CBD as in (a) in the presence or absence of 10mM JNK inhibitor for 4h. Western blot analysis was used to determine PARP and phospho-c-Jun expression.
Cleaved PARP is expressed as fold over control±S.E.M. for n¼four independent experiments. (h) LX-2 cells were treated with CBD in the presence or absence of JNK
inhibitor as in (g) for 8h. Cell viability was determined using an acid phosphatase assay and is expressed as mean±S.E.M. of triplicate experiments. ***Po0.001;
**Po0.01; *Po0.05
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Cell Death and Diseaseresponse in the pro-apoptotic effect of CBD. Using another
approach to block the ER stress response, we treated LX-2
cells with CBD in the presence of imatinib, which has been
shown to attenuate ER stress.
21 Imatinib led to a signiﬁcant
decrease in CHOP induction, JNK phosphorylation, and
PARP cleavage induced by CBD (Figure 6b), and protected
against CBD-mediated activated HSC death (Figure 6c),
providing strong evidence that CBD causes apoptosis by
promoting ER stress.
Basal level of ER stress determines apoptotic effect of
CBD. We then assessed the ER stress-mediated apoptotic
effect of CBD by examining its action in the presence or
absence of the ER stress inducer tunicamycin. We found that
CBD and tunicamycin worked in synergy to increase LX-2
cell death in a dose-dependent manner (Figure 7a),
supporting our ﬁnding that the apoptotic effect of CBD is
mediated through an ER stress mechanism.
In order to further elucidate the role of CBD-induced ER
stress as a mediator for apoptosis, we investigated the basis
for speciﬁcity of this occurrence in activated HSCs. We ﬁrst
examined basal ER stress levels in activated versus control
HSCs and found that expression levels of the ER stress
response genes ATF4, ATF6, and CHOP were increased in
activated HSCs from ethanol-treated rats as compared to
control HSCs from untreated rats (Figure 7b). This led us
to hypothesize that the elevated basal ER stress level of
activated HSCs rendered these cells more susceptible to the
ER stress-mediated apoptotic effect of CBD. To test this, we
treated control HSCs with tunicamycin and examined CHOP
expressionandPARPcleavagein thepresenceor absenceof
CBD. Interestingly, we found that increasing the basal level of
ER stress with tunicamycin in control HSCs led to an increase
in CBD-induced CHOP expression and HSC death
(Figure 7c). Taken together, this provided evidence that the
increased basal level of ER stress in activated HSCs is an
underlying factor, determining sensitivity to CBD and its
induction of ER stress-mediated apoptosis.
Discussion
As the central effector of liver ﬁbrosis, activated HSCs have
been the focus of many studies examining mechanisms
underlying the disease. The notion of activated HSCs as a
target for the treatment of liver ﬁbrosis
22 has stimulated
PARP
116 kDa
89 kDa
42 kDa β-Actin
CHOP 30 kDa
p-JNK
β-Actin
46 kDa
42 kDa
CBD
imatinib
-
-
+
-
+
-
-
+
+
+
+
+
c
l
e
a
v
e
d
 
P
A
R
P
(
f
o
l
d
 
o
v
e
r
 
v
e
h
i
c
l
e
)
C
H
O
P
(
f
o
l
d
 
o
v
e
r
 
v
e
h
i
c
l
e
)
CBD
imatinib
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
p
-
J
N
K
(
f
o
l
d
 
o
v
e
r
 
v
e
h
i
c
l
e
)
*** *** *
0
20
40
60
80
100
120
CBD
imatinib
-
-
+
-
-
+
+
+
0
5
10
15
0
1
2
3
4
5
6
7
0
1
2
3
4
5
6
7
PARP
β-Actin
CBD - + + - + +
control siRNA ATF4 siRNA
ATF4
CHOP 0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
A
T
F
4
(
f
o
l
d
 
o
v
e
r
 
c
o
n
t
r
o
l
)
0
1
2
3
4
c
l
e
a
v
e
d
 
P
A
R
P
(
f
o
l
d
 
o
v
e
r
 
v
e
h
i
c
l
e
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
C
H
O
P
(
f
o
l
d
 
o
v
e
r
 
v
e
h
i
c
l
e
)
CBD
ATF4 siRNA
control siRNA
-
-
+
+
-
+
-
+
-
+
+
-
-
-
+
+
-
+
-
+
-
+
+
-
-
-
+
+
-
+
-
+
-
+
+
-
116 kDa
89 kDa
30 kDa
38 kDa
42 kDa
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
* *** ***
***
Figure 6 Inhibition of ER stress response protects against CBD-induced cell death. (a) JS1 cells were transfected with siRNA against ATF4. After 16h, cells were
incubated with 5mM CBD in serum-free media for 8h. Western blot analysis was used to determine PARP, ATF4, and CHOP expression, presented as fold over
control±S.E.M.forn¼fourindependentexperiments.(b)LX-2cellsweretreatedwith5mMCBDinserum-freemediafor8hinthepresenceorabsenceof10mMimatinibto
inhibit ER stress. Expression of PARP, CHOP, and phospho-JNK was determined by western blot analysis and is presented as fold over vehicle±S.E.M. for n¼four
independent experiments. (c) Acid phosphatase activity was used to measure LX-2 cell viability following treatment with CBD and imatinib as in (b). Cell viability is expressed
as mean percent of control acid phosphatase activity±S.E.M. of triplicate experiments. ***Po0.001; **Po0.05
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Cell Death and Diseaseinvestigation of pathways that promote HSC apoptosis,
proposed as a means to facilitate disease regression.
23
Although a few antiﬁbrotic agents have been identiﬁed thus
far, including gliotoxin,
24 sulfasalazine,
25 and tectorigenin,
26
these compounds often lack cell-type speciﬁcity in targeting
activated HSCs.
27,28
Recently, the endocannabinoid system has been estab-
lished as a critical mediator of HSC activation and liver
ﬁbrosis,
29 and studies with various cannabinoid ligands have
demonstrated the therapeutic potential of this class of
molecules.
30 Interestingly, the phytocannabinoid CBD has
been found to lead to death of proliferative cells, such as
cancer cells and activated lymphocytes, through a variety of
processes involving either cannabinoid receptor-dependent
or -independent mechanisms.
31 The proliferative nature of
activated HSCs prompted us to examine the effect of CBD on
these cells.
Remarkably, we found that CBD induced death of activated
HSCs through apoptosis, an event that occurs independently
of cannabinoidreceptors.This led ustoinvestigatealternative
mechanisms for the pro-apoptotic effect of CBD. Alteration of
ER morphology, evidenced by changes in calnexin distribu-
tion and ER dilation, suggested that CBD induces ER stress.
This was conﬁrmed by activation of PERK, ATF6, and IRE1,
the three major mediators of the ER stress response, as well
as their downstream signaling cascades. Induction of CHOP,
indicative of prolonged ER stress and pro-apoptotic signaling,
further supported a CBD-induced ER stress response linked
to apoptosis. The downstream activation of the pro-apoptotic
ASK1/JNK cascade, known to be activated upon severe ER
stress, as well as our ﬁndings that expression of DN IRE1a
and inhibition of JNK both markedly suppressed the apoptotic
effect of CBD, provided evidence that CBD causes ASK1/
JNK-induced apoptosis in activated HSCs through an ER
stress-mediated mechanism.
Importantly, the apoptotic effect of CBD was speciﬁc to the
activated HSCs and could be seen in an activated HSC line
derived from ethanol-fed rats, in human LX-2 cells, as well as
in primary in vivo-activated HSCs from mouse. In contrast,
this effect was absent in primary rat hepatocytes and was
detectable in control HSCs only upon treatment with higher
concentrations of CBD.
As HSCs are the major ﬁbrogenic cells in the liver, their
production and secretion of excess ECM proteins is depen-
dent upon proper functioning of the ER. More so than in non-
proliferative or non-ﬁbrogenic cell types, the ER of activated
HSCs undergoes stress during excessive collagen produc-
tion, and maintaining homeostasis is likely aided by an
adaptive basal ER stress response. We ﬁnd that activated
HSCs have a higher basal level of ER stress, supported by an
upregulation of ATF4, ATF6, and CHOP mRNA expression in
activated HSCs (responsive to CBD) as compared with
control HSCs (not responsive to CBD). This could account
for the selectivity of the pro-apoptotic effect of CBD in
activated HSCs, wherein CBD exacerbates the pre-existing
ER stress response, thereby switching signaling from
adaptive to apoptotic. In line with this, inducing ER stress in
control HSCs with tunicamycin led to a sensitization of these
cells to CBD. Moreover, downregulation of ATF4 in untreated
activated HSCs led to decreased CHOP expression and
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Figure 7 Basal ER stress determines sensitivity to CBD. (a) LX-2 cells
were incubated in serum-free media with 0–4mM CBD for 6h in the presence
or absence of tunicamycin (1mg/mL) to induce ER stress. Cell death was detected
by western blot analysis of cleaved PARP, expressed as fold over vehicle±S.E.M.
for n¼three independent experiments. (b) Total RNA was extracted from whole
cell lysates of either ethanol-fed or control rat HSCs and reverse transcribed to
cDNA. Real-time PCR was performed with gene-speciﬁc primers for ATF4,
ATF6, and CHOP to determine the relative basal mRNA levels, normalized to
GAPDH and expressed as fold over control. ***Po0.001 (Student’s t-test). (c)E R
stress was induced in HSCs from control rats by incubation with the indicated
concentrations of tunicamycin in the presence or absence of 5mM CBD for 6h in
serum-free media. Cell death and ER stress were detected by western blot analysis
of PARP and CHOP expression, respectively. Cleaved PARP is expressed as fold
over control±S.E.M. for n¼three independent experiments. *Po0.05;
**Po0.01
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Cell Death and Diseaseapoptosis, suggesting that blocking the basal level PERK-
mediated ER stress response reduces sensitivity to CBD, and
that ER stress determines susceptibility to the pro-apoptotic
effect of CBD. These observations offer insight into ER stress
as a new intracellular pathway that could be targeted to
achieve antiﬁbrotic effects through selective elimination of
activated HSCs.
Although ER stress has been linked to many pathophysio-
logical processes,
15 our studies show for the ﬁrst time that it
may be involved in the activated HSC phenotype, and that ER
stress can be exploited in the context of hepatic ﬁbrosis to kill
speciﬁcally the HSCs that promote ﬁbrosis. Our ﬁnding that
CBD leads to activated HSC death independently of canna-
binoid receptors further underscores the novelty of the
mechanism proposed herein, in contrast to conventional
cannabinoid ligands that mediate antiﬁbrotic effects through
their cognate receptors.
30 Interestingly, other cannabinoid
ligands such as delta-9-tetrahydrocannabinol have been
shown to induce apoptosis in different cancer models such
as glioma cells and pancreatic tumor cells through a
mechanism involving ER stress,
32,33 dependent on cannabi-
noid receptor activation. This is reminiscent of the pro-
apoptotic effect of the CB2R-dependent CP55940-induced
HSC death that we observed, and suggests that CBD
promotes ER stress-induced apoptosis in activated HSCs
through a mechanism distinct from that of cannabinoid
receptor agonists.
In this study, we ﬁnd that CBD selectively kills activated
HSCs through the previously unexplored mechanism of ER
stress. We provide a molecular basis of action for CBD and
identify CBD as a novel potential therapeutic agent for liver
ﬁbrosis. These promising ﬁndings warrant future investigation
evaluating the antiﬁbrotic effect of CBD in vivo. The prospect
of CBD as a new antiﬁbrotic compound is rendered more
appealing by the fact that CBD is a non-psychoactive small
drug-like molecule already approved for clinical use in many
countries.
Materials and Methods
Materials. The following primary antibodies were used in this study: rabbit
monoclonal anti-phospho-JNK, rabbit polyclonal anti-JNK, anti-PARP, anti-P58IKP,
anti-eIF2a, anti-phospho-PERK, mouse monoclonal anti-CHOP (Cell Signaling
Technology, Danvers, MA, USA), polyclonal anti-calnexin, monoclonal anti-b-actin
(Sigma, St. Louis, MO, USA), rabbit polyclonal anti-ATF4, anti-ATF6, anti-XBP1,
anti-pASK1, phospho-c-Jun, anti-CHOP (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), monoclonal anti-a-SMA (Abcam, Cambridge, MA, USA), and polyclonal
anti-phospho-IRE1 (Novus Biological, Littleton, CO, USA). The following secondary
antibodies were used in this study: IRDye 680-labeled anti-rabbit, and IRDye 800-
labeled anti-mouse and anti-goat (Rockland Immunochemicals, Gilbertsville, PA,
USA). The following compounds were used in this study: CBD, AM630, JWH133,
PF514273, AM251, ACEA, AEA, 2-AG, CP55940, tunicamycin (Tocris Bioscience,
Ellisville, MO, USA), JNK inhibitor 2 (Calbiochem, Gibbstown, NJ, USA), imatinib
(Selleck Chemicals, Houston, TX, USA), and bis(p-nitrophenyl) phosphate (Sigma).
Cell culture. HSCs were maintained in DMEM/F12 50% v/vþ10% FBS. LX-2
cells
14 were a gift from Dr. Scott Friedman. HSCs from ethanol-treated and control
rats
13,34 were a gift from Dr. Natalia Nieto. JS1 cells (mouse activated HSCs) and
primaryHSCsfrommicethatwerechronicallyadministeredCCl4for1monthwerea
gift from Drs. Scott Friedman, Virginia Hernandez-Gea and Zahra Ghiassi-Nejad.
Primary rat hepatocytes were obtained from Invitrogen (Carlsbad, CA, USA) and
maintained according to manufacturer’s protocol.
Cell viability assay. Cell viability was determined using an acid phosphatase
assay as described.
35 Brieﬂy, cells were treated with vehicle (DMSO), CBD, or the
indicated ligands and drugs for indicated times, then washed with PBS. 10mM
bis(p-nitrophenyl) phosphate (substrate) in 165mM Na acetate buffer, pH 5.5,
containing 0.1% Triton X-100, was added to cells and incubated at room
temperature for 16–24h. Reaction was terminated by adding 1N NaOH, and the
absorbance at 410nM was measured using a spectrophotometer to determine acid
phosphatase activity.
Western blot. Western blot analysis was carried out as described.
36 Brieﬂy,
cells starved for 16h were treated with CBD or with the indicated compounds. Cells
were lysed in RIPA buffer and lysates were subjected to western blot analysis and
probed for the indicated proteins using speciﬁc antibodies, according to
manufacturer’s protocols. Both blotting and imaging with the Odyssey imaging
system (LI-COR, Lincoln, NE, USA) were performed following the manufacturer’s
protocols.
Flow cytometry. Cells were treated with vehicle or CBD for indicated times,
and stained with FITC-AnnexinV and propidium iodide (BD Biosciences, San Jose,
CA, USA), according to manufacturer’s protocol. Flow cytometric analyses were
performed on a three-laser LSRII with DiVa software (BD Biosciences). Data were
analyzed with FlowJo software (Tree Star Inc., Ashland, OR, USA).
Electron microscopy. Cells were ﬁxed with 3% glutaraldehyde, pH 7.4. The
specimens were then treated with 1% osmium tetroxide in 0.2M sodium cacodylate
for 1h, followed by ethanol dehydration in graded steps through propylene oxide,
and then embedded in Embed 812 (Electron Microscopy Sciences, Hatﬁeld, PA,
USA). Images were acquired on a Hitachi H7000 transmission electron microscope
(Hitachi, Tokyo, Japan).
Immunoﬂuorescenceandconfocalmicroscopy. Thiswascarriedout
as described.
36 Slides were visualized with a Leica TCS SP5 confocal microscope
(Leica Microsystems, Heidelberg, Germany). Images were acquired with an x63/
1.32 PL APO objective lens (Leica Microsystems) and analyzed in sequential
scanning mode.
Reverse transcription-polymerase chain reaction (RT-PCR). Cells
were treated with vehicle (DMSO) or CBD for indicated times, then washed
with PBS. Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Valencia,
CA, USA) and reverse transcribed using the High Capacity RNA-to-cDNA Kit
(Applied Biosystems, Carlsbad, CA, USA). cDNA from activated HSCs was
subjected either to standard PCR with Taq Polymerase (Invitrogen) to detect
splicing, or to real-time PCR with SYBR Green (Applied Biosystems) to detect
relativemRNAlevels. ForsplicedXbp1detectionby standardPCR, 500nMof eachrat
Xbp1-speciﬁc primers,
37 sense 50-AAACAGAGTAGCAGCACAGACTGC-30 and
antisense 50-TCCTTCTGGGTAGACCTCTGGGAG-30 were used with the following
program: (1) 941C for 4min, (2) 35 cycles of 941C for 45s, 631C for 30s, and 721C
f o r3 0 s ,a n d( 3 )7 2 1C for 10min. PCR products were separated by agarose gel
electrophoresistoresolvethe473bp(unspliced)and428bp(spliced)amplicons.Real-
timePCRwasperformedusingthefollowingprimers (500nM)forrat: ATF4sense50-T
ATGGATGGGTTGGTCAGTG-30 and antisense 50-CTCATCTGGCATGGTTTCC-30;
ATF6 sense 50-GATTTGATGCCTTGGGAGTC-30 and antisense 50-GGACCGA
GGAGAAGAGACAG-30; CHOP sense 50-CCACACCTGAAAGCAGAAAC-30 and
antisense 50-CACTGTCTCAAAGGCGAAAG-30;X B P 1s e n s e5 0-GATGAATGCCCT
GGTTACTG-30 and antisense 50-AGATGTTCTGGGGAGGTGAC-30; glyceraldehyde
3-phosphate dehydrogenase (GAPDH) sense 50-TCAAGAAGGTGGTGAAGCAG-30
and antisense 50-AGGTGGAAGAATGGGAGTTG-30; RNA polymerase II sense 50-G
AAGATCGGGAAGTGCTCAG-30 and antisense 50-ATCCGCAGAAGGTTACAAG
G-30; hypoxanthine-guanine phosphoribosyltransferase sense 50-CCCAAAATGGTT
AAGGTTGC-30 and antisense 50-TCAAGGGCATATCCAACAAC-30. Quantitative
analysis was performed using the DDCT method and REST software (http://
www.gene-quantiﬁcation.de).
38
DN IRE1a transfection. JS1 cells (mouse activated HSCs) were transfected
with Addgene plasmid 20745 (Addgene, Cambridge, MA, USA) coding DN IRE1a
(K599A, dominant negative kinase mutant), generated by Dr. Fumihiko Urano,
39
using Lipofectamine (Invitrogen). Stable lines were established by puromycin
selection and clonal growth of resistant cells. Similar results were observed with
three different clones. DN IRE1a expression was veriﬁed by RT-PCR using the
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Cell Death and Diseasehuman/mouse IRE1-speciﬁc primers, sense 50-CTCTATGCCTCTCCCTCAATG-30
and antisense 50-AAGTCCTTCTGCTCCACATACTC-30 (spanning the mutation
site), in JS1 wild-type cells, JS1 cells expressing DN IRE1a, and LX-2 cells,
according to the RT-PCR methods as described above. PCR products were
analyzed and puriﬁed by agarose gel electrophoresis, then sequenced using the
IRE1 antisense primer. GAPDH-speciﬁc primers for either human (sense 50-G
AAGGTGAAGGTCGGAGTC-30, antisense 50-GAAGATGGTGATGGGATTTC-30)
or mouse (sense 50-TGAAGGTCGGTGTGAACG-30, antisense 50-CAATCTCC
ACTTTGCCACTG-30) were used in parallel as internal controls.
siATF4 transfection. JS1cells in six-well plateswere transfectedwith Stealth
RNAisiRNAto ATF4(Invitrogen)for 6h usingLipofectamine(Invitrogen).Following
transfection, cells were serum-starved for 16h, and then treated with CBD for the
indicated times.
Statisticalanalyses. StatisticalsigniﬁcanceandP-valuesweredeterminedby
the Student’s t-test when comparing two groups, or by one-way ANOVA with
Bonferroni post test when comparing multiple groups, using the GraphPad Prism
software (GraphPad Software, San Diego, CA, USA). P-value (*Po0.05;
**Po0.01; ***Po0.001) of o0.05 was considered statistically signiﬁcant.
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